JP4684552B2 - 抗腫瘍類似体 - Google Patents

抗腫瘍類似体 Download PDF

Info

Publication number
JP4684552B2
JP4684552B2 JP2003519076A JP2003519076A JP4684552B2 JP 4684552 B2 JP4684552 B2 JP 4684552B2 JP 2003519076 A JP2003519076 A JP 2003519076A JP 2003519076 A JP2003519076 A JP 2003519076A JP 4684552 B2 JP4684552 B2 JP 4684552B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
carbon atoms
hydrogen
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003519076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501093A5 (https=
JP2005501093A (ja
Inventor
ヴァレンチン・マルチネス
ピラル・ガジェゴ
カルメン・クエヴァス
シモン・ムント
イグナシオ・マンサナレス
Original Assignee
ファルマ・マール・ソシエダード・アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9919954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4684552(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ファルマ・マール・ソシエダード・アノニマ filed Critical ファルマ・マール・ソシエダード・アノニマ
Publication of JP2005501093A publication Critical patent/JP2005501093A/ja
Publication of JP2005501093A5 publication Critical patent/JP2005501093A5/ja
Application granted granted Critical
Publication of JP4684552B2 publication Critical patent/JP4684552B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2003519076A 2001-08-07 2002-08-06 抗腫瘍類似体 Expired - Lifetime JP4684552B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119243.4A GB0119243D0 (en) 2001-08-07 2001-08-07 Antitumoral analogs of ET-743
PCT/GB2002/003592 WO2003014127A1 (en) 2001-08-07 2002-08-06 Antitumoral analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010209928A Division JP2011026331A (ja) 2001-08-07 2010-09-17 抗腫瘍類似体

Publications (3)

Publication Number Publication Date
JP2005501093A JP2005501093A (ja) 2005-01-13
JP2005501093A5 JP2005501093A5 (https=) 2010-11-18
JP4684552B2 true JP4684552B2 (ja) 2011-05-18

Family

ID=9919954

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003519076A Expired - Lifetime JP4684552B2 (ja) 2001-08-07 2002-08-06 抗腫瘍類似体
JP2010209928A Pending JP2011026331A (ja) 2001-08-07 2010-09-17 抗腫瘍類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010209928A Pending JP2011026331A (ja) 2001-08-07 2010-09-17 抗腫瘍類似体

Country Status (22)

Country Link
US (1) US7763615B2 (https=)
EP (3) EP1414828B9 (https=)
JP (2) JP4684552B2 (https=)
KR (1) KR20040032150A (https=)
CN (1) CN100334094C (https=)
AT (1) ATE374777T1 (https=)
AU (1) AU2002313540B2 (https=)
CA (1) CA2455768C (https=)
CY (1) CY1107830T1 (https=)
DE (1) DE60222775T2 (https=)
DK (1) DK1414828T3 (https=)
ES (1) ES2294151T3 (https=)
GB (1) GB0119243D0 (https=)
HU (1) HU229779B1 (https=)
IL (2) IL160051A0 (https=)
MX (1) MXPA04001240A (https=)
NO (1) NO337476B1 (https=)
NZ (1) NZ530837A (https=)
PL (1) PL218295B1 (https=)
PT (1) PT1414828E (https=)
RU (1) RU2283842C2 (https=)
WO (1) WO2003014127A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010215645A (ja) * 2002-02-04 2010-09-30 Pharma Mar Sau 自然に生じるエクチナサイジン及び関連化合物の合成

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) * 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
CN107033164A (zh) * 2010-05-25 2017-08-11 法马马有限公司 制备海鞘素化合物的合成方法
ME02395B (me) * 2010-11-12 2016-09-20 Pharma Mar Sa Kombinovana terapija sa antitumorskim alkaloidima
RU2562432C2 (ru) 2010-11-26 2015-09-10 Нек Корпорейшн Устройство видеокодирования, устройство видеодекодирования, способ видеокодирования, способ видеодекодирования и программа
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
TW202116783A (zh) 2019-09-03 2021-05-01 西班牙商瑪製藥股份有限公司 盧比克替定治療惡性間皮瘤
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
JP2023503318A (ja) * 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法
WO2021228414A1 (en) 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
KR20230004714A (ko) 2020-04-21 2023-01-06 파르마 마르, 에스.에이. 약물 항체 접합체
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
WO2022048775A1 (en) 2020-09-04 2022-03-10 Pharma Mar, S.A. Combination of lurbinectedin and immune checkpoint inhibitor
WO2022101255A1 (en) 2020-11-10 2022-05-19 Pharma Mar, S.A. Lurbinectedin and irinotecan combinations
IN202141039393A (https=) * 2021-08-31 2023-03-03
US20240415834A1 (en) 2021-11-08 2024-12-19 Pharma Mar, S.A. Lurbinectedin and atezolizumab combinations
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
CN115304619A (zh) * 2022-04-08 2022-11-08 上海皓元医药股份有限公司 一种卢比替定的晶型及其制备方法
CN114940682A (zh) * 2022-05-18 2022-08-26 博瑞制药(苏州)有限公司 芦比替定的晶型及其制备方法和用途
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
WO2024188978A1 (en) 2023-03-10 2024-09-19 Pharma Mar, S.A. Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer
WO2025059336A1 (en) * 2023-09-13 2025-03-20 Navinta, Llc An improved process for preparation of lurbinectedin
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
EP4563149A1 (en) 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用
WO2026022359A2 (en) 2024-07-26 2026-01-29 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CN1157189C (zh) 1998-04-06 2004-07-14 伊利诺伊大学评议会 半合成海鞘素
EP1077698B1 (en) 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
JP2003520801A (ja) * 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
JP5219323B2 (ja) * 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010215645A (ja) * 2002-02-04 2010-09-30 Pharma Mar Sau 自然に生じるエクチナサイジン及び関連化合物の合成

Also Published As

Publication number Publication date
IL160051A (en) 2012-01-31
JP2011026331A (ja) 2011-02-10
CN100334094C (zh) 2007-08-29
HUP0401174A3 (en) 2005-12-28
CN1564822A (zh) 2005-01-12
EP2270018A1 (en) 2011-01-05
EP1414828B9 (en) 2008-02-20
PL367940A1 (en) 2005-03-07
US7763615B2 (en) 2010-07-27
DK1414828T3 (da) 2008-02-04
AU2002313540B2 (en) 2008-05-22
CA2455768C (en) 2011-10-11
WO2003014127A1 (en) 2003-02-20
RU2283842C2 (ru) 2006-09-20
ATE374777T1 (de) 2007-10-15
DE60222775T2 (de) 2008-07-17
NO20040961L (no) 2004-03-05
GB0119243D0 (en) 2001-10-03
NZ530837A (en) 2005-07-29
HUP0401174A2 (hu) 2005-09-28
DE60222775D1 (de) 2007-11-15
EP1806349A1 (en) 2007-07-11
CA2455768A1 (en) 2003-02-20
US20060128711A1 (en) 2006-06-15
CY1107830T1 (el) 2013-06-19
PT1414828E (pt) 2007-12-27
KR20040032150A (ko) 2004-04-14
HK1065786A1 (en) 2005-03-04
ES2294151T3 (es) 2008-04-01
RU2004106617A (ru) 2005-04-10
PL218295B1 (pl) 2014-11-28
MXPA04001240A (es) 2004-06-03
IL160051A0 (en) 2004-06-20
EP1414828B1 (en) 2007-10-03
NO337476B1 (no) 2016-04-18
HU229779B1 (en) 2014-07-28
JP2005501093A (ja) 2005-01-13
EP1414828A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
JP4684552B2 (ja) 抗腫瘍類似体
AU2002313540A1 (en) Antitumoral analogs
US6124293A (en) Semi-synthetic ecteinascidins
Ning et al. Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2
NO340213B1 (no) Nye antitumorderivater av ecteinascidinen ET-743, farmasøytisk preparat derav og anvendelse derav ved fremstillingen av et medikament for behandling av en kreftsykdom
JP2005523275A (ja) 自然に生じるエクチナサイジン及び関連化合物の合成
AU2002317967A1 (en) New antitumoral derivatives of ET-743
HK1065786B (en) Antitumoral analogs
JP2009519301A (ja) 抗腫瘍化合物
NZ563054A (en) Antitumoral tetrahydro-pyrimidines
Daletos Isolation and Structure Elucidation of Bioactive Secondary Metabolites from Marine Sponges
HK1033651B (en) Semi-synthetic ecteinascidins

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100518

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100917

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110111

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110209

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140218

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4684552

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term